Acquisition of Magnesium Sulfate 2000 mg/10 ml Inj Solution Vial 10 ml IM IV - Year 2026

This tender concerns the acquisition of Magnesium Sulfate, a pharmaceutical product. The specific formulation is an injectable solution, with each 10 ml vial containing 2000 mg of Magnesium Sulfate. The administration routes indicated are Intramuscular (IM) and Intravenous (IV), highlighting its use in clinical settings for various medical treatments. Magnesium Sulfate is used to treat or prevent low blood magnesium levels and is also employed in managing conditions such as pre-eclampsia, eclampsia, severe asthma attacks, and certain cardiac arrhythmias. The procurement is essential for hospitals, clinics, and emergency medical services to ensure they have an adequate supply of this critical medication for patient care. The tender specifies the concentration, volume, and intended use, aiming to secure high-quality, sterile vials for medical administration. The reference to 'Year 2026' indicates this is a planned procurement for the upcoming year.

This is a supplies contract in the health and medical services sector, with a focus on Pharmaceuticals. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 8,974.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.